Dose Finding Study of GX-H9 in Paeditaric Patients With Growth Hormone Deficiency
Status:
Completed
Trial end date:
2019-05-15
Target enrollment:
Participant gender:
Summary
This is a randomized, open-label, active controlled, Phase 2 study designed to assess the
safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of weekly and
semi-monthly doses of GX-H9 in the treatment of Paediatric Growth Hormone Deficiency (PGHD)
as compared to the standard of care daily rhGH treatment.